Established in 1976, J.B.Chemicals & Pharmaceuticals Ltd. (JBCPL) is one of India’s fastest growing pharmaceutical companies. An integrated, research-oriented, public listed organisation with a focus on supplying affordable, quality products both in India and International markets, JBCPL is trusted by healthcare professionals globally.
JBCPL is widely committed to manufacturing a range of innovative
Established in 1976, J.B.Chemicals & Pharmaceuticals Ltd. (JBCPL) is one of India’s fastest growing pharmaceutical companies. An integrated, research-oriented, public listed organisation with a focus on supplying affordable, quality products both in India and International markets, JBCPL is trusted by healthcare professionals globally.
JBCPL is widely committed to manufacturing a range of innovative specialty products that include various pharmaceutical dosage forms like tablets, injectable (vials, ampoules, form fill seal), creams & ointments, lozenges, herbal liquids and capsules. In India and International markets, JBCPL is also known as Unique Pharmaceutical Laboratories and is a division of JBCPL.
JBCPL exports too many countries worldwide with presence in US, Europe, Australia, South Africa, other developing countries, Russia and CIS. The Company continues to invest in growing its share in the regulated markets such as USA, Europe and Australia. JBCPL has a strong R&D and regulatory set-up for development of new drug delivery system and formulations, filing of ANDAs and DMFs. Its state-of-the-art manufacturing facilities are approved by health authorities of key regulated markets.
Business area of the company
J. B. Chemicals & Pharmaceuticals is engaged in the business of manufacturing and marketing of diverse range of pharmaceutical formulations, herbal remedies and APIs.
Milestones & awards
1996-97
Shri. Dinesh Mody, Director, JBCPL, receiving the Prestigious National Export Award/Trophy for the year 1996-97, from the Hon’ble Prime Minister of India, Shri. Atal Behari Vajpayee
1999
2000
2001
2003
First ANDA filing with USFDA for Ciprofloxacin.
First company to market Rantac CD.
Approval from Columbian Drug Regulatory Authority INVIMA for its state-of-the-art facility at Panoli.
2004
Features in the Forbes Global list 100 for “Best under $1 Billion” in Asia-Pacific.
Receives its maiden USFDA approval to market Ciprofloxacin tablets in the US market.
UKMHRA approves JBCPL’s tablet manufacturing facility at Panoli.
2005
TGA Australia approves JBCPL’s tablet manufacturing facilities at Panoli, Gujarat, India.
JBCPL receives USFDA approval to market Fluconazole tablets in the US market.
JBCPL features in Forbes Asia Pacific 200 List for “Best under a Billion” for second year in a row.
2006
The ‘Niryat Shree’ Certificate of Excellence was awarded to Unique Pharmaceutical Laboratories Limited, a division of JBCPL, by the Federation of Indian Export Organisations (FIEO) for outstanding export performance in the category of Chemicals, Drugs, Pharma & Allied Products, Non-SSI for the year 2004-05.
2007
JBCPL’s Annual Report for the year ended March 31, 2005 was awarded a merit certificate by the South Asian Federation of Accountants (SAFA), an apex body of SAARC, for the Best Presented Accounts for the year 2005 in the category of “Hospitality, Health, Transport, Shipping, etc.’
2008
2011
2016
2017
Shri J. B. Mody, Chairman, receives Lifetime Achievement Award.
Mr. J. B. Mody’s Lifetime Achievement Award AV on 13-11-2017.
2018
2020
